Table 2 CCTA findings
Characteristic | No MACE (N = 1078) | MACE (N = 137) | P value |
|---|---|---|---|
CAD-RADS | 2 (1–3) | 3 (2–4) | < 0.001 |
 0 | 184 (17.1%) | 5 (3.6%) | < 0.001 |
 1–2 | 579 (53.7%) | 38 (27.7%) | < 0.001 |
 3–4 | 300 (27.8%) | 86 (62.8%) | < 0.001 |
 5 | 15 (1.4%) | 8 (5.8%) | < 0.001 |
High-risk plaque | 41 (3.8%) | 23 (16.8%) | < 0.001 |
Segment involvement score | 1 (1–3) | 3 (2–6) | < 0.001 |
 < 3 | 698 (64.7%) | 42 (30.7%) | < 0.001 |
 ≥ 3 | 380 (35.3%) | 95 (69.3%) | < 0.001 |
Segment stenosis score | 2 (1–4) | 6 (3–10) | < 0.001 |
 <5 | 841 (78.0%) | 56 (40.9%) | < 0.001 |
 ≥5 | 237 (22.0%) | 81 (59.1%) | < 0.001 |
Leiden risk score | 4.6 (1.2–10.2) | 11.2 (5.6–15.7) | < 0.001 |
 < 5 | 585 (54.3%) | 25 (18.2%) | < 0.001 |
 5–20 | 446 (41.4%) | 95 (69.3%) | < 0.001 |
 > 20 | 47 (4.4%) | 17 (12.4%) | < 0.001 |
Vessels affected | |||
 One-vessel disease | 251 (23.3%) | 20 (14.6%) | 0.02 |
 Two-vessel disease | 219 (20.3%) | 40 (29.2%) | 0.02 |
 Three-vessel disease | 211 (19.6%) | 57 (41.6%) | < 0.001 |
CACS | |||
 0 | 632 (58.6%) | 58 (42.3%) | < 0.001 |
 1–100 | 230 (21.3%) | 27 (19.7%) | 0.66 |
 100–300 | 99 (9.2%) | 17 (12.4%) | 0.23 |
 > 300 | 117 (10.9%) | 35 (25.5%) | < 0.001 |